Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats

Neuroscience Letters

Volumn 502, Issue 2, 2011, Pages 117-122

  Ren, Tiantian ^a   Yang, Xinxin ^b   Wu, Na ^b   Cai, Yunpeng ^a   Liu, Zhenguo ^b   Yuan, Weien ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

fosB; CAMP regulated phosphoprotein of 32kDa; Dopamine; Extracellular signal regulated kinases 1 and 2; Levodopa methyl ester(LDME) benserazide loaded microspheres; Levodopa induced dyskinesia; Parkinson's disease

Indexed keywords

BENSERAZIDE; DOPAMINE; LEVODOPA METHYL ESTER; MICROSPHERE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN DARPP 32; TRANSCRIPTION FACTOR DELTA FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DRUG DELIVERY SYSTEM; DYSKINESIA; FEMALE; FOREFOOT; IN VIVO STUDY; MALE; MICROENCAPSULATION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SUSTAINED RELEASE FORMULATION;

ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DRUG COMBINATIONS; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; REACTION TIME;

EID: 80051822766     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.07.042     Document Type: Article

References (27)

1. Arica B., Kas H.S., Moghdam A., Akalan N., Hincal A.A., Carbidopa Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J. Control. Release 2005, 102:689-697.
2. Aubert I., Guigoni C., Li Q., Dovero S., Bioulac B.H., Gross C.E., Crossman A.R., Bloch B., Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in l-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2007, 61:836-844.
3. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 2006, 23:2669-2676.
4. Bjorklund T., Carlsson T., Cederfjall E.A., Carta M., Kirik D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 2010, 133:496-511.
5. Bordet R., Ridray S., Carbon S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D-3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3363-3367.
6. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003, 14:404-416.
7. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
8. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
9. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
10. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
11. Geng Y., Yuan W., Wu F., Chen J., He M., Jin T. Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation. J. Control. Release 2008, 130:259-265.
12. Hemmings H., Greengard P., Tung H., Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984, 310:503-505.
13. Jaunarajs K.L., Dupre K.B., Steiniger A., Klioueva A., Moore A., Kelly C., Bishop C. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport 2009, 20:1265-1269.
14. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities. Mov. Disord. 2008, 23:S585-S598.
15. Kim D.S., Palmiter R.D., Cummins A., Gerfen C.R. Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 2006, 137:1381-1388.
16. Mabrouk O.S., Marti M., Salvadori S., Morari M. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 2009, 164:360-369.
17. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C.E., Bezard E., Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 2006, 22:586-598.
18. Morgese M.G., Cassano T., Cuomo V., Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 2007, 208:110-119.
19. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, Sydney.
20. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., Herve D., Greengard P., Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
21. Shen H., Kannari K., Yamato H., Arai A., Matsunaga M. Effects of benserazide on l-DOPA-derived extracellular dopamine levels and aromatic l-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J. Exp. Med. 2003, 199:149-159.
22. Sherer T.B., Betarbet R., Greenamyre J.T. Pathogenesis of Parkinson's disease. Curr. Opin. Investig. Drugs 2001, 2:657-662.
23. Silverdale M.A., Kobylecki C., Hallett P.J., Li Q., Dunah A.W., Ravenscroft P., Bezard E., Brotchie J.M. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010, 64:177-180.
24. Smith L.A., Jackson M.J., Al-Barghouthy G., Rose S., Kuoppamaki M., Olanow W., Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. 2005, 20:306-314.
25. Song L., Kong M., Ma Y., Ba M., Liu Z. Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats. Brain Res. 2009, 1276:171-179.
26. St-Hilaire M., Bourhis E., Levesque D., Rouillard C. Impaired behavioural and molecular adaptations to dopamine denervation and repeated l-DOPA treatment in Nur77-knockout mice. Eur. J. Neurosci. 2006, 24:795-805.
27. Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 2009, 1(Suppl. 3):S68-S71.